Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.1B
322M shares
52-week range
$2.23 – $6.51
29% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
P/S (TTM)
2.7
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
www.mannkindcorp.comNo one on the platform currently holds MNKD.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,868,442 | $4.6M |
| Execution date | Ratio |
|---|---|
| 2017-03-03 | 1-for-5reverse |
No one on the platform has traded MNKD yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 46.5% | — | — | — | ||
| Rev. Growth % | 22.2% | 39.9% | ||||
| Profit Margin % | 1.7% | -37.9% | -159.9% | |||
| Free Cash Flow Margin % | 3.9% | -34.9% | -110.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $443M | +29.5% | $-0.18 | $-0.24–$-0.13 | — | 5 |
| 2027 | $504M | +13.7% | $0.02 | $0.01–$0.04 | 146.9× | 5 |
| 2028 | $525M | +4.2% | $0.06 | $-0.29–$0.43 | 58.7× | 8 |
| 2029 | $592M | +12.8% | $0.17 | $0.15–$0.19 | 20.7× | 5 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | $-0.01 | $-0.06 | -700.0% |
| 2026-05-06 | $-0.02 | $-0.05 | -150.0% |
| 2026-02-26 | $-0.01 | $-0.05 | -400.0% |
| 2025-11-05 | $0.01 | $0.03 | +200.0% |
| 2025-08-06 | $0.04 | $0.00 | -94.6% |
| 2025-05-08 | $0.03 | $0.04 | +33.3% |
| 2025-02-26 | $0.03 | $0.03 | +0.0% |
| 2024-11-07 | $0.06 |
| $0.04 |
| -33.3% |
| $2.2B |
| — |
| HRMYHarmony Biosciences Holdings, Inc. | $41.53 | -1.35% | $2.4B | — |
| IMCRImmunocore Holdings plc | $32.42 | +0.75% | $1.6B | — |
Source: Financial Modeling Prep · peers by sector/industry
$MNKD just saw the Jonas boy advertising Dexcom on a DWTS commercial. Jeez, if Afrezza could attract and land him for some advertising
View on StockTwits ↗
$MNKD https://www.linkedin.com/in/brandon-mader/ Brandon Mader · 3rd Sr. Manager, DPI at United Therapeutics Corporation United Therapeutics Corporation Full-time · 1 yr 11 mos Durham, North Carolina, United States · On-site Sr. Manager, DPI Aug 2026 - Present · 2 mos Budget Manager on $550M project. FAT/SAT support for new building assets. Building team to support development and clinical trial materials for new DPI product. Manager, Manufacturing, Dry Powder Inhalation Nov 2024 - Aug 2026 · 1 yr 10 mos Bringing commercial product, Tyvaso®, to the RTP campus.
View on StockTwits ↗
$MNKD more wailing and gnashing of teeth coming longy way ... they love the pain ... lol
View on StockTwits ↗
$MNKD discussion on pediatric Afrezza study w pediatric endo involved with the study + two more endocrinologists who also use Afrezza along w their pumps. Lengthy but worth the time to listen. https://www.youtube.com/watch?v=mq_cgUFLoLQ
View on StockTwits ↗
$MNKD Mannkind 2016-2026 "The Lost Decade", at least for longs. For the shorts they probably call it "The Golden Years"
View on StockTwits ↗
$MNKD The BASHERS are out in force trying to spread FUD. I wonder if BlackRock did any due diligence before they bought 10% of this stock. How about the other big institutions that have more than 5%. Clearly some of the folks here think they are smarter than everyone. So do I.
View on StockTwits ↗$MNKD I went a little crazy this week buying more MNKD. My last few buys at $3.29 and $3.41 brought my other recent buys down way below my average per share which is $3.61. I hope all MNKD Longs took this buying opportunity. The crooks have known something for the last month or two....
View on StockTwits ↗$MNKD United Therapeutics plans to be the primary manufacturer of ralinepag DPI and they have built a new $500 million DPI manufacturing plant that they will be unveiling in October 2026. Mannkind has been quietly working with United Therapeutic since 2023, on the contstruction of the new DPI manufacturing plant and transferring the technology and know how to manufacturing Technosphere DPI. Hard to see how these two companies will not eventually join hands in a merger/buyout deal for all or part of Mannkind.
View on StockTwits ↗
$MNKD Well how about that! Come back from a doctors appointment and we are only down a penny for the day! Something really fishy is certainly going on here. BESIDES THE DAILY MINIPUILATION!!!
View on StockTwits ↗$MNKD I am a strong believer in Karma. People who lie, cheat and steal .....from others...will pay the price one day...I wish them the worst. Might be your bank account...your marriage...your pet or your kids.....but it will happen eventually..... I hope the worst for the scumbags who stole from us here. I will be watching and laughing at you all :)
View on StockTwits ↗
$MNKD Dilution IS coming. You can bury your head in the sand (again) and pretend we haven’t all seen this before, but we have, too many times not to know better. Our so-called CEO is the only one who profits from this endless cycle of debt-fuelled can kicking. Fire Mike.
View on StockTwits ↗
$MNKD humble enough to say i am at a loss here... revenue and prospects look like this should be at least market cap of $2B.... so, either this is an incredible buying opportunity (which is where my mind is at), or ???
View on StockTwits ↗
$MNKD Someone wanted out of this stock pretty badly. You ever wonder if maybe Sanofi was right. There is a reason Afrezza hasn’t gained traction. Could be the price is to high, tolerability issues such as cough or maybe it does not work as great as people think it does. We have herd so many excuses from management that it is utterly rediculous. There had to be a reason why UTHR is developing TreSMI. There has to be a reason why Yutrepia is taking share from us.
View on StockTwits ↗
$MNKD @Kuka somebody was winding down since it hit $3.25 at its low point today. Nobody was showing it love, especially institutional buyers. 16.30 million MNKD shares traded, versus only 4.53M yesterday and roughly 2–5.5M on most recent sessions.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.